Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mestag Therapeutics
The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.
In this latest installment of the VC Playbook series, In Vivo sits down with SV Health Investors’s Houman Ashrafian. The managing partner outlines the group’s investment philosophy, today’s skill set for VC success, and expectations for the future of Britain’s biotech industry post-Brexit and post-pandemic.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.